Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.

:be Aktie 113268981 / AT0000A2SGH0

07.11.2025 09:00:20

New XRP ETF Just Dropped, But Will Anything Be Different This Time?

Asset management firm Franklin Templeton recently submitted an amended S-1 filing to the SEC for its pending spot XRP exchange-traded fund (ETF), the Franklin XRP Trust. The amendment, dated November 4, 2025, includes one key regulatory difference from earlier versions that would likely affect the approval process for the XRP ETF.What’s Different About Franklin Templeton’s New XRP ETF FilingETF analyst James Seyffart shared the update on X (formerly Twitter), highlighting the removal of the 8(a) delay clause, which typically gives the SEC control over when a filing becomes effective. Usually, when an issuing firm files for an ETF, it includes what’s called a “delaying amendment.” This clause grants the SEC the authority to determine the exact time the filing takes effect. Franklin Templeton employed that standard wording in its earlier filings, including the initial submission on March 11, 2025, and a subsequent amendment on August 22, 2025.The latest filing, however, shortens that delaying condition. Instead, it states that the registration “shall hereafter become effective in accordance with the provisions of section 8(a) of the Securities Act of 1933.” Under this rule, the Franklin spot XRP ETF registration automatically becomes effective 20 days after filing, unless the SEC intervenes. The Franklin XRP Trust will primarily hold XRP as its primary asset and track the token’s market price, with Coinbase Custody managing asset storage and BNY Mellon overseeing cash holdings. The trust seeks a listing on the Cboe BZX Exchange, adopting a structure similar to other recently approved crypto ETFs.A Growing Trend Of Fast-Tracked Crypto ETF FilingsFranklin Templeton’s update isn’t happening in isolation. Other asset managers, including Bitwise and Canary Funds, have also made similar changes to their S-1 filings for XRP ETFs in recent weeks, cutting back on the delay wording that typically allows the SEC to set the launch timeline.The growing series of S-1 changes demonstrates how these ETF issuers are reclaiming control over the timing of XRP ETF approvals. Journalist Eleanor Terrett highlighted this trend on X, noting that it has become more common since the US government shutdown in October. During that period, the SEC’s review process slowed, prompting many asset managers to use the timing rule to expedite their filings.The issuing companies may also be using the same “fast-track” rule that helped other spot crypto ETFs such as Solana (SOL), Litecoin (LTC), and Hedera (HBAR) launch last month. By shortening the delay provision, Franklin Templeton’s XRP ETF now follows the same accelerated path and may receive approval before the end of November.While the SEC can still intervene, this change indicates that XRP ETF issuers are gaining more control over approval timing by adopting faster pathways, signaling that this time, things could indeed be different.Weiter zum vollständigen Artikel bei NewsBTC

Analysen zu :be AG Inhaber-Akt

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
Zu diesem Datensatz liegen uns leider keine Daten vor.
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

Abnehmspritzen – Ist der Hype vorbei? – mit Tim Schäfer

Ist der Hype um Abnehmspritzen wie bei Novo Nordisk und Eli Lilly vorbei – oder stehen wir erst am Anfang einer langfristigen Revolution im Gesundheitswesen? 💉📉

Im heutigen Gespräch mit Tim Schäfer @TimSchaeferMedia sprechen wir über die spannendsten Pharmawerte 2025. Neben den Abnehmspritzen blicken wir auch auf klassische Pharma-Giganten wie Pfizer, Johnson & Johnson, Roche, Novartis, AstraZeneca und GSK. Tim analysiert Übertreibungen, Rücksetzer und langfristige Chancen für Buy-and-Hold-Strategien – mit Fokus auf Dividende, KGV und Krisenresistenz.

💬 Was ist vom Abnehmtrend langfristig zu halten?
💬 Welche Pharma-Aktien sind aktuell unterbewertet?
💬 Was spricht für konservative Dividendenwerte im Gesundheitssektor?

👉🏽 https://bxplus.ch/wall-street-live-mit-tim-schaefer/

Abnehmspritzen – Ist der Hype vorbei? – Wall Street Live mit Tim Schäfer

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 12’777.17 19.22 BWDSCU
Short 13’015.63 13.98 UBSIIU
Short 13’525.87 8.82 BTASKU
SMI-Kurs: 12’220.63 07.11.2025 12:35:36
Long 11’746.18 19.52 SHFB5U
Long 11’497.82 13.90 SK0BIU
Long 10’994.16 8.91 S4FB0U
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com